Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 21, 2026, titled ""Orbicular s Partner secures tentative U.S. ANDA approval for a generic version of Ozempicr (Semaglutide Injection), supported by OneSource as CDMO partner"".